Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer
Authors:
- Clara HelalCHClara Helal
- Léa PinonLPLéa Pinon
- Juliette JinJJJuliette Jin
- Niccolo SchintuNSNiccolo Schintu
- Ana VazquezAVAna Vazquez
- Léna DomalainLDLéna Domalain
- Martin NurmikMNMartin Nurmik
- Gianni AntonelliGAGianni Antonelli
- Ségolène LadaigueSLSégolène Ladaigue
- Maxime SimonMSMaxime Simon
- Elodie MontaudonEMElodie Montaudon
- Laura SourdLSLaura Sourd
Open Access
- 28 August 2026
- journal article
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (9)
Abstract
No abstract availableFunding Information
- Fondation de France (00149014/WB-2023-50799)
- HORIZON EUROPE Framework Programme (101136464)
- Institut National de la Santé et de la Recherche Médicale
- Agence Nationale de la Recherche (ANR-24-EXME-0005 \u2013 PEPR MEDOOC \u2013 TME-on-Chip)
This publication has 61 references indexed in Scilit:
- Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living GuidelineAnnals of Oncology, 2025
- Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expressionCPT: Pharmacometrics & Systems Pharmacology, 2024
- The Applications and Challenges of the Development of In Vitro Tumor Microenvironment ChipsCellular and Molecular Bioengineering, 2022
- Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinationsCancer Cell, 2021
- Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast CancerAdvanced Science, 2021
- Prostate cancer patient‐derived organoids: detailed outcome from a prospective cohort of 81 clinical specimensThe Journal of Pathology, 2021
- Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid TumorsClinical Pharmacology & Therapeutics, 2020
- A Living Biobank of Breast Cancer Organoids Captures Disease HeterogeneityCell, 2018
- Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signaturesBreast Cancer Research and Treatment, 2012
- Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenograftsBreast Cancer Research and Treatment, 2011